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Background: Heat shock protein 70 (Hsp70) is an intracellular chaperone protein with regulatory and
cytoprotective functions. Hsp70 can also be found in the extracellular milieu, as a result of active secretion or
passive release from damaged cells. The role of extracellular Hsp70 is not fully understood. Some studies report that
it activates monocytes, macrophages and dendritic cells through innate immune receptors (such as Toll-like
receptors, TLRs), while others report that Hsp70 is a negative regulator of the inflammatory response. In order to
address this apparent inconsistency, in this study we evaluated the response of human monocytes to a highly
purified recombinant Hsp70.
Methods: Human peripheral blood monocytes were stimulated with Hsp70, alone or in combination with TLR
agonists. Cytokines were quantified in culture supernatants, their mRNAs were measured by RT-PCR, and the
binding of transcription factors was evaluated by electrophoretic mobility shift assay (EMSA). Kruskal-Wallis test or
one-way or two-way ANOVA were used to analyze the data.
Results: The addition of Hsp70 to TLR-activated monocytes down-regulated TNF-α as well as IL-6 levels. This effect
was independent of a physical interaction between Hsp70 and TLR agonists; instead it resulted of changes at the
TNF-α gene expression level. The decrease in TNF-α expression correlated with the binding of HSF-1 (heat shock
transcription factor 1, a transcription factor activated in response to Hsp70) and CHBF (constitutive HSE-binding
factor) to the TNF-α gene promoter.
Conclusion: Extracellular Hsp70 negatively regulates the production of pro-inflammatory cytokines of monocytes
exposed to TLR agonists and contributes to dampen the inflammatory response.
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Inflammation occurs in response to infection, heat shock
or cellular stress. During infection, increased levels of
Heat shock protein 70 (Hsp70) confer cytoprotection [1]
by inhibiting components of inflammatory signaling
pathways, such as the NF-κB transcription factor [2].
Hsp70 is predominantly an intracellular protein, but it
can be released to the extracellular milieu as a result of
tissue damage or cellular necrosis [3]. Moreover, the
presence of extracellular Hsp70 in the absence of cell
death, suggests that live cells actively secrete Hsp70 [4].
It has been proposed that Hsp70 functions as an alarmin
[5], as it can be detected in the plasma of healthy indi-
viduals and at higher concentrations in the serum of se-
verely traumatized patients, patients with autoimmune
diseases and inflammatory conditions, and children with
septic shock [6-9]. The transcription of Hsp70 is medi-
ated by the activation of heat shock transcription factor-
1 (HSF-1), which binds to the heat shock element (HSE)
in the Hsp70 gene promoter [10]. Interestingly, HSF-1 is
a negative regulator of TNF-α release in a mouse model
of lipopolysaccharide (LPS)-induced shock, and it re-
presses the transcription of mouse TNF-α and IL-1β
[11]. The identification of a functional HSE in the hu-
man TNF-α promoter suggests that HSF-1 directly par-
ticipates in the regulation of TNF-α expression [12,13].
Increased levels of extracellular Hsp70 have been re-
ported to stimulate an inflammatory response via a Toll-
like receptor 2 (TLR2)/TLR4/CD14-dependent mechan-
ism that leads to NF-κB activation, and TNF-α, IL1-β
and IL-6 production [14]. However, other reports show
that extracellular Hsp70 induces LPS tolerance and pre-
vents the augmentation of pro-inflammatory cytokines
levels that follows LPS stimulation [15]. The immune-
stimulating activity of Hsp70 through TLR2 and TLR4
remains thus controversial, and it has been proposed
that the pro-inflammatory activity of Hsp70 results ra-
ther of contaminating LPS [16]. Furthermore, a pro-
inflammatory role of extracellular Hsp70 would be diffi-
cult to reconcile with the role of intracellular Hsp70,
which mainly regulates apoptosis and confers cytopro-
tection [1,17]. In fact, data from the HSP70 1/3 knock-
out mice suggests that extracellular Hsp70 is important
for the negative regulation of inflammatory mediators
during systemic infection [18].
In this study, we evaluated the role of extracellular
Hsp70 on the inflammatory response elicited by different
TLR agonists central to the early onset of innate im-
mune responses to bacterial infections.
Methods
Reagents
Recombinant human stress induced Hsp70 (Hsp72) was
purchased from Enzo Life Sciences (formerly AssayDesigns, and formerly Stressgen Biotechnologies Cor-
poration). We tested conventional, non-LPS-free Hsp70
(NSP-555), which we will refer to as “HE/Hsp70”; and
LPS-free Hsp70 (ESP-555), which we will refer to as
“Hsp70”. The non-LPS free HE/Hsp70 contains 200 pg
of LPS per μg of protein, while the LPS-free Hsp70 con-
tains 1.4 pg of LPS per μg of protein (fewer than 50 IU
of LPS), as assessed by the Limulus amebocyte lysate
assay in our laboratory. According to the manufacturer,
both Hsp70preparations retain their ATPase activity. To
heat-denature Hsp70, the protein was boiled for 120 min.
Escherichia coli 0111:B4 LPS was from Sigma Chemical
Co. (St. Louis, MO, USA); Salmonella typhimurium flagel-
lin and Staphylococcus aureus peptidoglycan were from
Invivogen (San Diego, CA, USA), and vaccine-grade Sal-
monella enterica serovar Typhi porins, with < 200 pg of
LPS per μg of protein, were obtained in our laboratory as
previously reported [19].
Cell separation and stimulation
Peripheral blood mononuclear cells from leukocyte con-
centrates of healthy blood bank donors were isolated with
Lymphoprep™ (Axis-Shield, Oslo, Norway). Mononuclear
cells were resuspended in 2 ml of RPMI 1640 supple-
mented with 10% fetal bovine serum and 1% penicillin-
streptomycin (all reagents were from GIBCO Invitrogen,
Carlsbad, CA, USA), counted and plated at 20 × 106 cells
per 15 ml in a culture dish for 2 h at 37°C. The
monocytes-enriched fraction was detached with cold
buffer (NaCl 0.8%, KCl 0.04%, glucose 0.1%, sodium
EDTA 0.02% and NaHCO3 0.6%) and plated at 1 × 10
6
cells per well in 24-well plates for 24 h at 37°C and 5%
CO2 in supplemented RPMI. All experiments were per-
formed with mononuclear cells enriched for monocytes by
at least 85% as assessed by flow cytometry expression.
After 24 h, the culture medium was removed and cells
were washed twice with phosphate-buffered saline before
adding fresh supplemented RPMI with or without LPS
(100 ng/ml), peptidoglycan (10 μg/ml), flagellin (10 μg/ml)
or porins (3 μg/ml). The TLR agonists were added alone
or in the presence of the indicated amounts of Hsp70 in
1 ml of RPMI, for the indicated times. Supernatants were
then collected, centrifuged (3,000 rpm for 5 min), and
frozen at −70°C. Alternatively, TLR agonists were pre-
incubated with Hsp70 in 200 μl of binding buffer
(25 mM TRIS, 20 mM HEPES, 47.5 mM KCl, and
2.25 mM Mg(OAc)2, pH 7.15) for two hours at 37°C, be-
fore adding them to the cells.
Cell separation and stimulation for flow cytometric
analysis of TLR expression
Peripheral blood mononuclear cells were obtained from
leukocyte concentrates of healthy blood-bank donors by
gradient centrifugation with Lymphoprep™ (Axis-Shield,
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2 ml of RPMI 1640 supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin (all reagents from
GIBCO Invitrogen, Carlsbad, CA, USA), counted and
seeded at 0.5 × 106 cells per tube and incubated in a hu-
midified incubator with 5% CO2 and 37°C.Cytokine quantification
The concentrations of TNF-α, IL-6 and IL-10 in cell
culture supernatants were measured with ELISA kits
(BD Biosciences Pharmingen, San Jose, CA, USA), accord-
ing to the manufacturers’ protocols.PCR quantification
The TNF-α mRNA was analyzed by RT-PCR. Total RNA
was extracted from monocytes using TRIzol reagent
(Invitrogen). The concentration and purity of RNA were
determined at 260 and 280 nm. Single-stranded cDNA
was synthesized by mixing 1 μg RNA with 1 μl of oligo-
dT(12–18) (0.5 μg/μl, Invitrogen), 1 μl of a dNTP mixture
(10 mM each), 2 μl of 0.1 M dithiotreitol and 200 U of
SuperScript II RNase H reverse transcriptase in a total
volume of 20 μl; the reaction mixture was incubated at
42°C for 50 min, followed by 70°C for 15 min to inacti-
vate the reverse transcriptase. cDNA (1 μg) was used as
a template for PCR amplification of the TNF-α gene.
The PCR reaction mixture consisted of 0.5 μl of a dNTP
mixture (10 mM each), 1.5 μl of 25 mM MgCl2, 1 μl of
primer working stock (10 pmol of each primer), 0.25 μl
of dimethilsulfoxide (Sigma) and 1.25 U of Taq DNA
polymerase in a total volume of 20 μl (all reagents were
from Promega, Madison, WI, USA, unless otherwise
indicated). The TNF-α primers were 5′-GGT-GCT-
TGT-TCC-TCA-GCC-TC-3′ and 5′-CAG-GCA-GAA-
GAG-CGT-GGT-G-3′ [20] and the β-actin primers
were 5′-GTG-GGG-CGC-CCC-AGG-CAC-CA-3′ and
5′-CTC-CTT-AAT-GTC-ACG-CAC-GAT-TTC-3′ [21].
β-actin was used as an internal control in each experi-
ment. The reaction mixture was denatured at 95°C for
10 min, followed by 35 cycles of denaturation (95°C/
30 s), annealing (58°C/1 min), and extension (72°C/
1 min); the final extension was for 10 min. The PCR
products were separated by electrophoresis in agarose
gels at 70 V for 60 min, stained with ethidium bromide
and observed by ultraviolet illumination. Images were
captured and analyzed with an IS-1000 Digital Imaging
System (Alpha-Innotech Corporation, San Leandro,
CA, USA). The pixel densities of TNF-α and β-actin
bands were determined and the ratios of TNF-α to β-
actin were calculated; these ratios represent the rela-
tive expression levels or expression index of TNF-α
mRNA.Electrophoretic mobility shift assay (EMSA)
To prepare nuclear extracts, monocytes were lysed in
1 ml of cold buffer A (10 mM Tris–HCl pH 7.4, 10 mM
NaCl, 6 mM MgCl2, 10 mM NaF, 1 mM Na3VO4, 1 mM
dithiotreitol, and 1 mM phenylmethanesulfonyl fluoride)
and incubated on ice for 10 min. After this incubation,
10 μl of IGEPAL 10% were added, and the tubes were in-
cubated for another 5 min at 4ºC on a shaking platform.
The lysates were centrifuged at 2,600 rpm for 5 min, re-
suspended in 40 μl of cold buffer B (20 mM HEPES,
pH 7.9, 420 mM NaCl, 20% glycerol, 1.5 mM MgCl2,
0.2 mM EDTA, 1 mM Na3VO4, 10 mM NaF, 1 mM
DTT, and 0.2 mM PMSF) and incubated for 15 min at
4ºC on a shaking platform. Nuclear extracts were recov-
ered by centrifugation at 12,000 rpm for 15 min at 4°C
and frozen at −70°C. Total protein concentration was
measured using a commercial reagent (Bio-Rad Labora-
tories, Hercules, CA, USA) and a bovine serum albumin
standard curve. To evaluate the binding of HSF-1 to the
promoter region of the human TNF-α gene, we used a
double-stranded oligonucleotide that corresponds to
the +45/+73 position of the TNF-α sequence (5′-AGA-
GAA-GCA-ACT-ACA-GAC-CCC-CCC-TGA-AA-3′) and
contains specific binding sites for HSF-1 (in boldface). The
oligonucleotide was labeled with [γ-32P] ATP with a T4
polynucleotide kinase (Fermentas, Thermo Scientific, Glen
Burnie, MD, USA), according to the manufacturer’s
protocol. The 32P-labelled oligonucleotide probe (1 ng)
was incubated with 5 μg of nuclear extract in the pres-
ence of 3 μg poly(dI-dC) in 0.25 M HEPES, pH 7.5,
0.6 M KCl, 50 mM MgCl2, 1 mM EDTA, 7.5 mM DTT
and 9% glycerol) for 20 min at 4°C. We added a 50-fold
excess of unlabeled TNF-α probe (“cold”) or an irrelevant
oligonucleotide (5′-ACG-TGT-GAT-GAA-ATG-CTA-
GGC-GAT-C-3′) as specific and non-specific competi-
tors, respectively. After incubation, samples were resolved
on 6% polyacrylamide gels in 0.5x Tris borate-EDTA
buffer (74.5 mM Tris–HCl, 1.6 mM sodium EDTA, and
44.5 mM boric acid pH 8.5) for 4 h at 0.28 mA. The gels
were dried and analyzed by autoradiography with a
Kodak intensifying screen (Carestream Health, Rochester,
NY, USA) at −80°C.Fluorescence-activated cell sorting (FACS) analysis of TLR
and CD14 expression
FACS was performed to detect cell surface expression of
TLR2, TLR4 on CD14 cells after Hsp70 stimulation. Hu-
man mononuclear cells were exposed to 3 μg/ml Hsp70
for 1 or 4 hours, and then the cells were harvested and
washed twice with PBS containing 1% BSA. Cells were in-
cubated with FITC-conjugated anti-TLR2, PE-conjugated
anti-TLR4 (eBioscienced) and Pacific Blue-conjugated
anti-CD14 (BioLegend), at room temperature for 30 min.
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try (Becton-Dickinson).
Statistical analysis
Each experiment was performed three or four times with
independent donors. Data were analyzed with GraphPad
Prism 5.0 software (GraphPad Software, San Diego, CA,
USA). Kruskal-Wallis test, one-way or two-way ANOVA
were used as required, followed by Dunn’s multiple com-
parison test, Tukey or Bonferroni post-tests. A P value <
0.05 was considered statistically significant.
Results
Hsp70 decreases the production of TNF-α by LPS-
activated monocytes
Hsp70 is released by cell injury secondary to infections
[7], and some authors have proposed that extracellular
Hsp70 is a TLR2 and/or TLR4 agonist that induces the
production of pro-inflammatory cytokines [22], while
other authors argue that an LPS contamination of the
Hsp70 used in these experiments is accountable for the
inflammatory response [16,23]. To re-examine these
possibilities, we evaluated the capacity of LPS-free Hsp70
to trigger the production of the pro-inflammatory cytokine
TNF-α by human monocytes. We confirmed that extracel-
lular Hsp70 signals through TLR2 and TLR4 as it induced
the recruitment of NF-κB to DNA (Additional file 1:
Figure S1). However stimulation with Hsp70 (3 μg/ml)
for different times (0, 3, 6,12, 24 and 48 h) as well as
with concentrations ranging from 0.03 to 3 μg/ml did
not induce TNF-α production (Figure 1A and B). Inter-
estingly, TNF-α concentration was lower when mono-
cytes were exposed to LPS-free Hsp70 in comparison
with non-stimulated monocytes (Figure 1B); although
this difference was not statistically significant, it was
consistent through all experiments. In contrast, non-
LPS-free HE/Hsp70 clearly induced the production of
TNF-α (Figure 1D).
Hsp70 has been reported to inhibit some components
of the pro-inflammatory signaling cascades [2]. To inves-
tigate this possibility, we added LPS-free Hsp70 and LPS
to the same well, and found that Hsp70 considerably de-
creased the amount of TNF-α secreted by monocytes in
response to LPS. This effect was lost if the Hsp70 was
heat-denatured before the assay (Figure 1C). To assess if
Hsp70 prevented LPS-induced TNF-α transcription, we
examined the levels of TNF-α mRNA in LPS-activated
monocytes. Hsp70 reduced the TNF-α mRNA levels
resulting of a 2 or 6 hr LPS stimulation (Figure 1E) with
similar results at 1, and 4 h after LPS activation (data
not shown). The reduced mRNA levels correlated with
lower levels of TNF-α in the supernatants (Figure 1F).
Hsp70 had no effect on the surface expression of TLR2
and TLR4 (Additional file 2: Figure S2).Altogether this data support the hypothesis that LPS-
free Hsp70 is not a pro-inflammatory signal for the cell,
and furthermore that it dampens TNF-α production.
Hsp70 regulates LPS-dependent TNF-α production
through a mechanism that does not depend on the direct
interaction between LPS and Hsp70
In order to further characterize the effect of Hsp70, we
first performed a checkerboard assay on monocytes in-
cubated with different amounts of LPS and LPS-free
Hsp70 and measured TNF-α production. The inhibitory
effect of HSP-70 on TNF-α production is dose-dependent.
As little as 3 ng/ml of Hsp70 significantly reduced the
amount of TNF-α produced in response to 100 ng/ml of
LPS (Figure 2A) and 3 μg/ml abolished the TNF-α pro-
duction in response to 100 ng/ml of LPS by 34%, but
not that in response to 1000 or 10000 ng/ml of LPS
(Figure 2B).
The ability of Hsp70 to reduce the amount of TNF-α
produced in response to LPS could result of the physical
association between LPS and Hsp70, potentially interfer-
ing with TLR4 signaling. To test this possibility, we used
a “two-step” stimulation model (Figure 2C). Monocytes
were first stimulated with LPS or Hsp70 for 2 or 4 h,
after which, the wells were extensively washed with cul-
ture medium and fresh culture medium with Hsp70 or
LPS was added. In the upper left panel of Figure 2D, the
“TNF-α values shown at 2/4 hours for the LPS + Hsp70
and Hsp70 samples represent the amount of TNF-α
present in those wells at the time where the Hsp70 was
additioned to the cells”. Therefore, as expected, there is
no significative difference between the TNF-α values in
the LPS wells and the LPS-Hsp70 wells at the 2 hr or
4 hr point for the right upper panel of Figure 2D. These
values shaw the “evolution” of TNF-α release prior to
Hsp70 addition, as all cells were seeded at the same time
(Figure 2D, top panels). The TNF-α values shown at 2/
4 hours for the LPS +Hsp70 and Hsp70 samples repre-
sent the amount of TNF-α present in the wells at the
time where the Hsp70 was additioned to the cells. Like-
wise, addition of LPS did not rescue TNF-α production
when added after Hsp70, even though Hsp70 was no
longer present (Figure 2D, bottom panels).
These data suggests that, depending on the concentra-
tion, Hsp70 can override LPS-mediated signals, and that
this effect does not depend on the ability of Hsp70 to
directly interact with LPS.
Hsp70 decreases the production of TNF-α, but not that of
IL-10, in response to TLR agonists
To assess whether the capacity of Hsp70 to inhibit TNF-α
production was restricted to LPS, we sought to stimulate
human monocytes with other TLR agonists: Staphylococ-
cus aureus peptidoglycan, a TLR2 agonist; Salmonella










































































































































Figure 1 Hsp70 decreases the production of TNF-α by LPS-activated human monocytes. A. Monocytes were left unstimulated (NS) or
stimulated with Hsp70 (3 μg/ml) or LPS (100 ng/ml) for the indicated time and TNF-α concentration was measured in the supernatants. Two-way
ANOVA with Bonferroni post-test: ***P < 0.001 LPS vs. Hsp70. B. Monocytes were unstimulated (NS) or stimulated with different concentrations of
Hsp70 (3, 0.3 and 0.003 μg/ml) or LPS (100 ng/ml) and the amount of TNF-α in the culture supernatant was measure at the indicated time.
Two-way ANOVA with Bonferroni post-test: ***P < 0.001 LPS vs. Hsp70. C. Monocytes were non stimulated (NS) or stimulated for 6 h with
LPS-purified Hsp70 (3 μg/ml), LPS (100 ng/ml), Hsp70 and LPS or LPS and heat-denatured Hsp70 (Hsp70 D) as described in material and methods.
TNFα production was determined after 6 hr in the culture supernantant. Kruskal-Wallis test with Dunn’s multiple comparison test: *P < 0.05.
D. Monocytes were non stimulated (NS) or stimulated for 6 h with LPS-purified Hsp70 (3 μg/ml), LPS (100 ng/ml) or non-LPS-purified Hsp70 (HE/
Hsp70, 3 μg/ml) and TNFα production was determined after 6 hr in the culture supernantant. Kruskal-Wallis test with Dunn’s multiple comparison
test: *P < 0.05. E. Monocytes were cultured non treated (NS) or cultured with LPS (100 ng/ml) in the presence or absence of Hsp70 (3 μg/ml) for 2
or 6 hrs, and the expression levels of TNF-α mRNA were evaluated. β-actin was amplified simultaneously to verify RNA integrity and to ensure that
equivalent amounts of templates were used. F. TNF-α production by the monocytes in E at four different times 1, 2, 4 and 6 hrs. Kruskal-Wallis test
with Dunn’s multiple comparison test: *P < 0.05. NS = non-stimulated cells. Data is representative of 3 independent assays.
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Figure 2 Hsp70 regulates LPS-dependent TNF-α production through a mechanism that does not depend on the interaction between
LPS and Hsp70. A. Monocytes were stimulated for 6 h in the presence of Hsp70 (3000 to 0.003 ng/ml) and 100 ng/ml of LPS. B. Monocytes
were stimulated for 6 h in the presence of LPS (10000 to 1 ng/ml) and 3 μg/ml of Hsp70. LPS was pre-incubated with Hsp70 in 200 μl of binding
buffer for 2 h at 37°C, before adding them to the corresponding wells. TNF-α production was determined after 6 hr in the culture supernantant.
One-way ANOVA with Tukey’s post-test: ***P < 0.001 LPS vs. LPS + Hsp70. Data is representative of 3 independent assays. C. Schematic representation
of the experimental design. D, top panels. Monocytes were cultured in the absence (NS) or in the presence of LPS (100 ng/ml) for 2 or 4 h. After this
incubation, fresh culture medium with Hsp70 (3 μg/ml) was added (LPS + HSp70). The cells were incubated for 24 h. As controls, LPS (100 ng/ml) or
Hsp70 (3 μg/ml) were added to the cells. The amount of TNF-α was measured in the supernatants at the indicated time points. D, bottom panels.
Monocytes were left unstimulates (NS) or cultured with Hsp70 (3 μg/ml) for 2 or 4 h. After this incubation, fresh culture medium with LPS (100 ng/ml)
was added (Hsp70 + LPS). As controls, LPS (100 ng/ml) or Hsp70 (3 μg/ml) were added to the cells. The cells were incubated for a total of 24 h. The
amount of TNF-α was measured in the supernatants at the indicated time periods. Two-way ANOVA with Bonferroni post-test: ***P < 0.001 LPS vs.
Hsp70 + LPS or vs. LPS + Hsp70. NS = non-stimulated cells. Data is representative of 3 independent assays.
Ferat-Osorio et al. Journal of Inflammation 2014, 11:19 Page 6 of 12
http://www.journal-inflammation.com/content/11/1/19enterica serovar Typhi porins, TLR2 and TLR4 agonists
[24]; Escherichia coli LPS, a TLR4 agonist and, Salmonella
typhimurium flagellin, a TLR5 agonist. The addition of
Hsp70 clearly lowered the production of TNF-α by mono-
cytes in response to all TLR agonists. Hsp70 also reduced
the amount of the pro-inflammatory cytokine IL-6 re-
leased in response to LPS but interestingly had no effect
on IL-6 production in response to flagellin, peptidoglycan
or porins. In contrast, the addition of Hsp70 did not im-
pact the levels of the anti-inflammatory cytokine IL-10secreted in response to LPS or any other TLR agonists
(Figure 3). These results show that Hsp70 selectively af-
fects the production of pro-inflammatory cytokines such
as TNF-α, but not that of anti-inflammatory ones such as
IL-10.
Hsp70-induced binding of HSF-1 to the TNF-α promoter
correlates with decreased TNF-α protein levels
The mouse TNF-α promoter contains a binding site for
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Figure 3 Hsp70 decreases the production of TNF-α and IL-6, but not that of IL-10, in response to TLR agonists. Monocytes were left
untreated (NS) or cultured for 48 h in the presence of LPS (100 ng/ml), flagellin (10 μg/ml), peptidoglycan (PG) (10 μg/ml) and porins (3 μg/ml),
alone or in the presence of Hsp70 (3 μg/ml). TLR agonists were pre-incubated with Hsp70 in 200 μl of binding buffer for 2 h at 37°C, before
adding them to the corresponding wells. The concentrations of TNF-α, IL-6 and IL-10 were measured in the supernatants at the indicated time
periods. Two-way ANOVA with Bonferroni post-test: *P < 0.05; **P < 0.01; ***P < 0.001 each TLR agonist vs. each TLR agonist + Hsp70. NS = non-stimulated
cells. Data is representative of 3 independent assays.
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TNF-α production we detected with Hsp70 in LPS-
activated human monocytes involved HSF-1 recruitment,
we evaluated the interaction of this transcription factor
with the promoter region of the human TNF-α gene by
EMSA (Figure 4). Consistent with the literature, two dis-
tinct HSE-binding complexes were identified: a slower-
migrating complex corresponding to the binding of HSF-1
to the HSE in the TNF-α gene promoter, and a faster-
migrating complex corresponding to the binding of CHBF
(constitutive HSE-binding factor, also known as Ku auto-
antigen) to HSE [25,26]. We found that HSF-1 as well as
CHBF constitutively bound to the promoter region of the
TNF-α gene in resting cells, but that they were highly
enriched (4-fold approximately) in Hsp70-activated cells
with both proteins recruited in equivalent amounts. Co-
stimulation with LPS and Hsp70 favored the formation of
the faster migrating complex (CHBF binding) in addition
to the slower migrating complex (HSF-1 binding). Stimu-
lating the cells with LPS resulted in the recruitment of
HSF-1 only and the faster migrating complex appears
60 min following stimulation, albeit in a smaller propor-
tion as compared to HSP70- or HSP70/LPS-stimulatedcells (Figure 4, top panels). The specificity of the inter-
action of HSF-1 with the TNF-α promoter was demon-
strated by inhibition of the formation of the HSF-1
complex in the presence of a 50-fold excess of a “cold”
competitor, while an irrelevant competitor had no effect
on the binding. As expected, a heat shock (performed by
incubating the monocytes at 42°C for the indicated times)
also induced the binding of HSF-1 to the TNF-α promoter
(Additional file 3: Figure S3). The decrease in TNF-α
concentration in the supernatants in response to LPS +
Hsp70, compared to the amount of TNF-α in response
to LPS alone, correlates with the increased binding of
HSF-1 to the TNF-α promoter in response to LPS +
Hsp70 (Figure 4, bottom panels). Altogether, these data
suggest that Hsp70 negatively controls TNF-α gene
transcription by recruiting HSF-1 and CHBF to the TNF-α
gene promoter.
Discussion
An increasing number of diseases result of a dysregulated
inflammatory response, and several inflammatory media-
tors, including Hsp70, have been implicated. The molecu-
lar chaperone Hsp70 has many functions depending on
Figure 4 The effect of Hsp70 on LPS-induced TNF-α production depends on the binding of HSF-1 and CHBF to the TNF-α promoter.
Top panels. Monocytes were stimulated with Hsp70 (3 μg/ml), LPS (100 ng/ml) or Hsp70 + LPS for 15, 30, 60 and 120 min, at 37°C. Non-stimulated cells
were used as a negative control (−) and monocytes cultured at 42°C for the indicated times (heat-shock, HS) were used as a positive control. After
incubation, nuclear extracts were obtained and analyzed by EMSA, using the TNF-α probe. The autoradiography is representative of 3 independent
experiments. The slower migrating complex, corresponds to the binding of HSF-1 to the HSE in the TNF-α promoter, and the faster migrating complex,
corresponds to the binding of CHBF to the HSE. Control included EMSA reaction with 50-fold excess cold TNF-α competitor or 50-fold excess irrelevant
competitor. Bottom panels. The levels of TNF-α were determined in the supernatant of the same cultures; data is from 3 independent experiments.
Two-way ANOVA with Bonferroni post-test: ***P < 0.001.
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play, especially the extracellular form, remains incomplete,
and is even controversial [27-32]. Two members of the
HSP70 family, Hsp73 and Hsp72, share a high degree of
sequence homology but differ in their expression pattern:
Hsp73 is constitutively expressed, while Hsp72 is stress-
inducible [33]. In resting cells, Hsp73 is found mainly in
the cytoplasm, the nuclei and nucleoli, while Hsp72 is
found in nuclei and nucleoli. However, after a stressful
event, such as heat shock, the distribution of both forms is
homogenized throughout the cell, suggesting that both
isoforms associate with similar molecules to protect essen-
tial cell structures [34]. Incubation of human monocytes
with Hsp70 –the inducible form- was reported to have a
functional consequence by eliciting the rapid expression
of pro-inflammatory cytokines [14]; whereas Hsp73
does not induce any significant release of IL-6 – a pro-
inflammatory cytokine by monocytes [35].
Some authors have reported that extracellular Hsp70
functions as a DAMP and activates monocytes, macro-
phages and dendritic cells, potentially through cell surface
receptors such as CD14, CD40, CD91, Lox1, TLR2 and
TLR4 [36]. In different experimental models [14,22,37-39],
Hsp70 has been found to induce intracellular calcium
fluxes and NF-κB activation, with the subsequent produc-
tion of the pro-inflammatory cytokines TNF-α, IL-1β, IL-6
and IL-8. However, Hsp70 is present in the peripheral
circulation of healthy subjects at concentrations that,
according to these studies, would elicit cytokine produc-
tion [8], suggesting that Hsp70 is not pro-inflammatory inall contexts [40,41]. In fact, intracellular Hsp70 has a
cytoprotective effect, as it inhibits the production of in-
flammatory mediators during cellular stress [42]. Our
results support a cytoprotective role for Hsp70 whereby
it diminishes the production of the pro-inflammatory
mediator TNF-α, through the recruitment of HSF-1 tran-
scription factor to the cytokine promoter, thus extending
its cytoprotective role beyond the intracellular space to
the extracellular milieu.
Data shown here bring also evidence that extracellular
Hsp70 not only fails to induce TNF-α production in hu-
man monocytes, but that it down-regulates their capacity
to produce TNF-α and IL-6 in response to LPS. The
Hsp70 (LPS-free HSP70) we used in our experiments cor-
responds to the inducible isoform (Hsp72); as a result of a
multi-step chromatography purification process it has very
low levels of LPS (<50 endotoxin units/mg) and could not,
by itself, induce cytokine production by human mono-
cytes. These results are consistent with reports that at-
tribute the immune-stimulating activity of Hsp70 to
contaminating LPS [16,43], and others that show that
in patients with rheumatoid arthritis, extracellular
Hsp70 decreased IL-6, IL-8 and MCP-1 production in-
duced by TNF-α [44]. Likewise, recombinant Hsp72
(induced Hsp70) has been reported to lessen the sever-
ity of collagen-induced arthritis in mice, by lowering
serum TNF-α and IL-6 concentration [45].
We used a highly purified commercial Hsp70 for our
experiments (purified by multi-step chromatography,
with <50 endotoxin units/mg); this Hsp70 corresponds
Ferat-Osorio et al. Journal of Inflammation 2014, 11:19 Page 9 of 12
http://www.journal-inflammation.com/content/11/1/19to the inducible isoform (Hsp72), and it is not bound to
any other molecule. However, we cannot exclude the
possibility that Hsp70 bound another protein or peptide
in the cell culture supernatants. This binding, as well as
its ADP/ATP-binding status, could modify the effects of
Hsp70 on human monocytes [46]. These two aspects
need to be evaluated in future studies. The recombinant
Hsp70 that we used is produced in E. coli, so it is possible
that its conformation is different from that of native
Hsp70 in cells. However, this Hsp70 from Enzo Life Sci-
ences, formerly Stressgen retains its ATPase activity, and
we observed that it activates NF-κB through TLR2 and
TLR4 signalling, as has been reported previously which
suggest that the recombinant protein retains a conform-
ation compatible with its biological activity [16,47].
Hsp70 interacts with highly hydrophobic peptides [48].
TLR agonists usually have hydrophobic regions that bind
to the leucine-rich-repeats (LRR) domain-groove of
TLRs [49]. The binding of a TLR agonist to Hsp70 could
interfere with its ability to engage its TLR, and the sub-
sequent signaling cascade leading to cytokine production
would be defective. Our results do not support this pos-
sibility. Data we report here suggest rather that the effect
of Hsp70 on LPS-induced TNF-α production is inde-
pendent of a physical association with LPS, because the
addition of LPS after monocytes were treated with Hsp70
did not lead to TNF-α production, even though Hsp70
was no longer present in the system. Furthermore, our re-
sults indicating that Hsp70 activates NF-κB through TLR2
and TLR4 signaling argues against the possibility that
Hsp70 inhibit LPS-mediate TNF-α expression by nega-
tively modulating TLR4 expression. In fact, we found that
Hsp70 has no effect on the surface expression of TLR2
and TLR4 on monocytes, consistent with a report showing
that Hsp70 does not affect TLR2 nor TLR4 expression on
mouse macrophages [50].
TNF-α production by human peripheral blood mono-
nuclear cells was reduced by more than 50% when the
cells were cultured with LPS in the presence of Hsp70,
but that incubating these cells with 15 to 60 μg/ml of
Hsp70 for 24 h increased TNF-α production in response
to 1 ng/ml of LPS [43]. This apparent discrepancy with
our results could be caused by the different concentrations
of Hsp70 and LPS used, and by the use of peripheral blood
mononuclear cells instead of enriched monocytes for the
experiments.
Endotoxemia stimulates stress responses through HSF-1,
as a protective mechanism for the host. HSF-1 is found
in the cytoplasm as a monomer devoid of transcrip-
tional activity, but upon exposure to a heat shock or to
other stressing insults, it is phosphorylated, trimerized
and transported to the nucleus, where it binds to HSEs.
Extracellular Hsp70 phosphorylates Akt through the
TLR4 signaling pathway, resulting in glycogen synthasekinase (GSK)-3β inactivation [51]. The inactivation of
GSK-3β, an inhibitory regulator of HSF-1, leads to in-
creased HSF-1 activity [52]. CHBF interacts also with
HSE and competes with HSF1 for binding to DNA [53].
The mouse TNF-α promoter contains an HSE binding
site for HSF-1 and binding of HSF-1 this HSE results in
repressed transcription [12]. Based on the location of
the putative HSE in the human TNF-α gene promoter,
HSF-1 and CHBF could hinder the RNA polymerase
processivity [12]. In our experimental system, we pro-
vide evidence that the decrease in TNF-α production
caused by Hsp70 in LPS-activated monocytes results of
a change at the gene expression level: the amount of
TNF-α mRNA was decreased in the presence of Hsp70.
We report that monocyte co-stimulation with LPS and
Hsp70 lead to HSF-1 and CHBF binding to the HSE on
the TNF-α promoter, and that this binding correlated
with a decreased production of TNF-α. As expected,
unstressed cells contained mainly the slower migrating
complex. These data are consistent with the fact that
heat shock, which increases the levels of HSF-1, has a
suppressive effect on the inflammatory response, pos-
sibly because HSF-1 exerts a competitive inhibition on
NF-κB binding [54]. We observed that Hsp70 activates
NF-κB through TLR2 and TLR4 signaling (Additional
file 1: Figure S1). However, the activation of this tran-
scription factor did not lead to TNF-α production,
probably as a result of the strong activation of HSF-1.
The reduction of IL-6 production in our model could
be explained because HSF-1 inhibits the expression of
this cytokine through activating transcription factor 3
(ATF-3) [55].
Interestingly, we found that Hsp70 treatment pre-
vented LPS-induced IL-6 expression but not that result-
ing from engaging TL2 (porins) o TLR5 (flagellin).
Unlike TLR2 and TLR5, TLR4-induced IL-6 expression
involves the activation of the JAK-STAT pathway, thus
making IL-6 expression susceptible to the negative
regulation of SOCS1 [56]. Noteworthy, T. gondii Hsp70
promotes SOCS1 expression in macrophages [57]. Thus, it
is possible that by inducing SOCS1 expression H70 specif-
ically preventsTRL-4 induced JAK-STAT-dependent IL-6
expression, without affecting that resulting from TLR2 or
TLR5 signaling.
A previous paper reported that exogenous recombinant
Hsp70 interacts with HSF-1 in cell lines. The authors find
that Hsp70 binds to HSF-1 and blocks its DNA-binding
activity, and they suggest a model in which this association
prevents the transcription of HSF-1-regulated genes in
resting cells. After a heat shock, miss-folded proteins com-
pete for Hsp70 binding, and this releases HSF-1 [58]. In
our study, we did not explore the signalling pathways that
lead to HSF-1 activation, but a similar mechanism could
operate during inflammation-induced cell stress. Other
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levels of TNF-α after stimulation with LPS [59], and that
Escherichia coli-induced inflammation is resolved faster
when a heat shock precedes inoculation with bacteria [60].
HSF-1 also inhibits the transcription and secretion of
G-CSF in response to LPS [61]. Furthermore, HSF-1 has
been reported to prevent the overproduction of pro-
inflammatory cytokines in conditions such as sepsis
[62], potentially decreasing the inflammation-associated
damage. Our results support the idea that exogenous
HSP70 provides a mechanism for controlling the exces-
sive expansion of an inflammatory response after mono-
cytes activation by bacterial pathogens through the
recruitment of HSF-1 to the human TNF-α promoter,
and underscores a potential role for exogenous Hsp70
as a prophylactic agent for different types of inflamma-
tory diseases associated with infections.
Conclusion
Extracellular Hsp70 negatively regulates the production
of pro-inflammatory cytokines of monocytes exposed to
TLR agonists and contributes to dampen the inflamma-
tory response.Additional files
Additional file 1: Figure S1. Hsp70 activates NF-κB through TLR2 and
TLR4 signaling. Peripheral blood mononuclear cells were blocked with
5 μg of anti-TLR2 antibody (iTLR2) and/or 30 μg of anti-TLR4 antibody
(iTLR4). After 30 min, cells were washed and stimulated with 3 μg of
Hsp70, 100 ng of LPS or 10 μg of peptidoglycan (PGN) for 120 min. After
this incubation, nuclear extracts were obtained and analyzed by EMSA.
The EMSA was performed as indicated in Material and Methods, using a
double-stranded oligonucleotide that contains specific binding sites for
NF-│B (5′–AGC-TAA-GGG-ACT-TTC-CGC-TGG-GGA-CTT-TCC-AGG–3′). Control
included EMSA reaction with 50-fold excess cold NF-│B competitor or 50-fold
excess irrelevant competitor. The autoradiography is representative of two
independent experiments. The NF-κB complex is indicated (arrow).
Additional file 2: Figure S2. Hsp70 has no effect on the surface
expression of TLR2 and TLR4 on monocytes. Human peripheral blood
mononuclear cells (5 × 105) were stimulated with 3 μg/ml Hsp70 or
100 ng/ml of LPS (as a positive control of cellular activation) for 1 (a-b) or
4 hours (c-d). Surface expression of TLR2 (a-c) and TLR4 (b-d) in
CD14+ cells was analyzed by flow cytometry after staining the cells with
FITC-conjugated anti-TLR2, PE-conjugated anti-TLR4 and Pacific
Blue-conjugated anti-CD14 (BioLegend) at room temperature for 30 min.
TLR expression was normalized and is shown as fold expression, relative
to untreated cells (NS). Data represent the mean ± SD of three
independent experiments.
Additional file 3: Figure S3. Heat-shock induces HSF-1 binding to the
human Hsp70 promoter. Peripheral blood mononuclear cells were
incubated at 42°C for 1 h (heat-shock, HS), or stimulated with 100 ng/ml
of LPS and incubated at 37°C for 1 h and nuclear extracts were obtained
and analyzed by EMSA. The EMSA was performed as indicated in Material
and Methods, using a double-stranded oligonucleotide that corresponds
to the −107/-83 position of the human Hsp70 promoter sequence
(5′–CCC-CTG-GAA-TAT-TCC-CGA-CC–3′) containing an ideal HSE (in boldface).
Two distinct HSE-binding proteins can be detected in this mobility shift assay:
arrows indicate the HSF-1 slower migrating complex and the CHBF
faster migrating complex. The autoradiography is representative of
three independent experiments.Abbreviations
Hsp70: Heat shock protein 70; TLR: Toll-like receptors; RT-PCR: Reverse
transcription polymerase chain reaction; EMSA: Electrophoretic mobility shift
assay; TNF-α: Tumor necrosis factor alfa; IL-6: Interleukine 6; IL-10: Interleukine
10; NF-κB: Nuclear factor kappa B; HSF-1: Heat shock transcription factor 1;
HSE: Heat shock element; CHBF: Constitutive HSE-binding factor.
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